Physician profile
Peter Lee
NPI 1124101654
$5,186.85
in general payments reported to CMS, 2019-2025
31 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $461 · 2021: $748 · 2022: $973 · 2023: $873 · 2024: $594 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363 · Education: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.05 |
| Education | $526.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.99 | 2019-2025 | |
| Lilly USA, LLC | $562.28 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $556.59 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $407.98 | 2020-2024 | Ilumya, Odomzo, Blu-U |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $331.51 | 2019-2023 | Jublia, Arazlo, Duobrii |
| Novartis Pharmaceuticals Corporation | $328.08 | 2019-2025 | |
| Genzyme Corporation | $255.01 | 2021-2025 | |
| Leo Pharma INC. | $239.57 | 2019-2025 | Adbry |
| Celgene Corporation | $231.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $220.63 | 2019-2025 | Libtayo |
| Pfizer INC. | $163.77 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $140.52 | 2020-2021 | |
| Incyte Corporation | $128.82 | 2022 | |
| Amgen INC. | $111.20 | 2020-2025 | Otezla, Otezla |
| Eli Lilly and Company | $99.00 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $92.93 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $76.67 | 2022-2023 | Naftin |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Galderma Laboratories, L.P. | $58.74 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $47.06 | 2019-2024 | Sotyktu |
| Almirall LLC | $45.45 | 2021-2022 | |
| Genentech USA, INC. | $29.45 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $26.36 | 2019 | |
| Journey Medical Corporation | $24.48 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $21.32 | 2021 | |
| Dusa Pharmaceuticals, INC. | $16.79 | 2019 | |
| Biofrontera INC. | $14.41 | 2021 | |
| Ucb, INC. | $13.93 | 2021 | |
| Nabriva Therapeutics, Plc | $13.49 | 2022 | |
| Organon LLC | $12.25 | 2025 | Vtama |
| Acorda Therapeutics, INC | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.